A groundbreaking and ethically charged development in biotechnology has emerged, with two stealth startups, R3 Bio and Kind Biotechnology, reportedly advancing research into creating "nonsentient" bodies or "organ sacks" for transplant purposes. Tech journalist Ashlee Vance highlighted the radical nature of this work, tweeting, "> And now we shall have organs on demand. The wildest story you will read today." This controversial approach aims to address the critical global shortage of donor organs, but it has ignited significant ethical discussions among scientists and the public.
R3 Bio, co-founded by John Schloendorn and Alice Gilman, initially presented its work as developing "monkey organ sacks" to replace lab animals. However, investigations by MIT Technology Review revealed a more ambitious vision pitched to investors: genetically engineered, brainless human clones intended for organ harvesting or even full body replacement for longevity enthusiasts. The company denies allegations of intent to create human clones, though Gilman stated the team "reserves the right to hold hypothetical futuristic discussions."
Kind Biotechnology, led by Justin Rebo, is similarly focused on cultivating integrated organ systems within genetically modified animals. Using CRISPR gene-editing, KindBio has reportedly produced mice lacking complete brains, faces, or limbs, aiming for "a sack of organs that grows mostly on its own." Rebo emphasizes an "ethical and scalable" way to produce organs, noting the thousands who die awaiting transplants.
The concept has drawn sharp criticism from bioethicists and scientists. Jose Cibelli, a Michigan State researcher known for cloning human embryos, questioned the safety and ethics, stating, "There is no limit to human imagination and ways to make money, but there have to be boundaries. And this is the boundary of making a human being who is not a human being." Harvard professor George Church, an advisor to Kind Bio, acknowledged the "repulsive" nature of growing entire brainless bodies, suggesting a more focused approach on single organs.
Proponents argue that a nonsentient body would be ethically acceptable for organ harvesting, potentially offering a solution to the organ crisis and a path to extreme life extension. However, the reliance on surrogacy for human clones and the difficulty in defining consciousness in such entities remain significant hurdles. The "yuck factor" associated with these technologies is expected to generate considerable public backlash as these developments move from stealth to public discourse.
